

Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following any-grade adverse events was most commonly reported in patients receiving camizestran for ER-positive mBC in the Phase II SERENA-2 trial?**
 - Bleeding
 - Dyschromia
 - Photopsia**
 - Hypophosphatemia
- 2. The novel antiestrogen vepdegestran belongs to which of the following functional classes?**
 - Aromatase inhibitor
 - PROTAC**
 - SERM
 - SERD
- 3. Elacestrant is FDA approved for which of the following patients with ER-positive, HER2-negative advanced breast cancer?**
 - Those with ESR1 wild-type disease
 - Those with ESR1-mutated disease**
 - Those with ESR1-mutated and ESR1 wild-type disease
- 4. Which of the following best describes progression-free survival (PFS) results with the addition of capivasertib to fulvestrant for previously treated HR-positive advanced breast cancer in the Phase III CAPitello-291 trial?**
 - PFS was not significantly improved
 - PFS was significantly improved in the all-comer population**
 - PFS was significantly improved only in patients with AKT pathway-altered tumors
- 5. Which of the following any-grade adverse events was most commonly reported in patients receiving imlunestran in combination with abemaciclib for ER-positive, HER2-negative advanced breast cancer in the Phase Ib EMBER trial?**
 - Nausea**
 - Bruising
 - Dry mouth
 - Nail changes